These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32485634)

  • 1. Efficacy and safety of rituximab in multiple sclerosis: Experience from a developing country.
    Mathew T; John SK; Kamath V; Murgod U; Thomas K; Baptist AA; Therambil M; Shaji A; Nadig R; Badachi S; Souza DD; Shivde S; Avati A; Sarma GRK; Sharath Kumar GG; Deepalam S; Parry GJ
    Mult Scler Relat Disord; 2020 Aug; 43():102210. PubMed ID: 32485634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus.
    Leonidou E; Pantzaris M; Kleopa KA; Loizidou MA; Kyriakides T; Christou YP
    Postgrad Med; 2019 Sep; 131(7):486-489. PubMed ID: 31353999
    [No Abstract]   [Full Text] [Related]  

  • 3. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
    Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
    Zecca C; Bovis F; Novi G; Capobianco M; Lanzillo R; Frau J; Repice AM; Hakiki B; Realmuto S; Bonavita S; Curti E; Brambilla L; Mataluni G; Cavalla P; Di Sapio A; Signoriello E; Barone S; Maniscalco GT; Maietta I; Maraffi I; Boffa G; Malucchi S; Nozzolillo A; Coghe G; Mechi C; Salemi G; Gallo A; Sacco R; Cellerino M; Malentacchi M; De Angelis M; Lorefice L; Magnani E; Prestipino E; Sperli F; Brescia Morra V; Fenu G; Barilaro A; Abbadessa G; Signori A; Granella F; Amato MP; Uccelli A; Gobbi C; Sormani MP
    Mult Scler; 2020 Oct; 26(12):1519-1531. PubMed ID: 31573386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.
    Yamout BI; El-Ayoubi NK; Nicolas J; El Kouzi Y; Khoury SJ; Zeineddine MM
    J Immunol Res; 2018; 2018():9084759. PubMed ID: 30539030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the efficacy and safety of Zytux
    Naser Moghadasi A; Darki A; Masoumi P; Hashemi SN; Ghadiri F
    Mult Scler Relat Disord; 2019 Nov; 36():101419. PubMed ID: 31586800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of rituximab in Mexican patients with Multiple Sclerosis-A single-center retrospective study.
    Bribiesca-Contreras E; García-Estrada C; Gómez-Figueroa E; Zertuche-Ortuño L; Rodríguez-Rivas R; Marcín-Sierra M; Delgado-Niño M; Rivas-Alonso V; Corona-Vázquez T; Flores-Rivera J
    Mult Scler Relat Disord; 2022 Feb; 58():103485. PubMed ID: 35042092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis.
    Starvaggi Cucuzza C; Longinetti E; Ruffin N; Evertsson B; Kockum I; Jagodic M; Al Nimer F; Frisell T; Piehl F
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
    Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
    JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Rituximab on Expanded Disability Status Scale and Relapse Rate in Multiple Sclerosis Patients.
    Mazdeh M; Khamseh M; Taheri M; Ghafouri-Fard S
    J Mol Neurosci; 2020 Aug; 70(8):1165-1168. PubMed ID: 32144724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious safety events in rituximab-treated multiple sclerosis and related disorders.
    Vollmer BL; Wallach AI; Corboy JR; Dubovskaya K; Alvarez E; Kister I
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1477-1487. PubMed ID: 32767531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.
    Scotti B; Disanto G; Sacco R; Guigli M; Zecca C; Gobbi C
    PLoS One; 2018; 13(5):e0197415. PubMed ID: 29758075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rituximab in patients with multiple sclerosis: An observational study at a tertiary center in Makkah, Saudi Arabia.
    Almatrafi YM; Babakkor MA; Irfan M; Samkari ET; Alzahrani WM; Mohorjy DK; Zahoor S; Farooq MT; Sajid Jehangir HM
    Neurosciences (Riyadh); 2022 Apr; 27(2):65-70. PubMed ID: 35477910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in multiple sclerosis at general hospital level.
    Hellgren J; Risedal A; Källén K
    Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland.
    Airas L; Nylund M; Mannonen I; Matilainen M; Sucksdorff M; Rissanen E
    Mult Scler Relat Disord; 2020 May; 40():101980. PubMed ID: 32066031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with rituximab therapy in a real-life sample of multiple sclerosis patients.
    Bellinvia A; Prestipino E; Portaccio E; Razzolini L; Fonderico M; Fratangelo R; Tudisco L; Pastò L; Amato MP
    Neurol Sci; 2020 Oct; 41(10):2939-2945. PubMed ID: 32350672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.
    Gascón-Giménez F; Alcalá C; Ramió-Torrentà L; Montero P; Matías-Guiu J; Gómez-Estevez I; Oreja-Guevara C; Gil-Perotín S; Blanco Y; Carcelén M; Quintanilla-Bordás C; Costa L; Villar LM; Martínez-Rodriguez JE; Domínguez JA; Calles C; González I; Sotoca J; Oterino A; Lucas-Jimenez C; Pérez-Miralles F; Casanova B
    Front Neurol; 2023; 14():1060696. PubMed ID: 36959824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.